

as IPAC members of the opportunity to be considered for the IPAC.

**DATES:** Statements of Interest received on or before September 14, 2020 will be given consideration for selection to the IPAC for appointment in 2020.

**ADDRESSES:** Individuals who are interested in being considered for the IPAC may submit a Statement of Interest to [IPAC@frb.gov](mailto:IPAC@frb.gov). The Statement of Interest collects only contact information. Candidates may also choose to provide additional information for consideration as part of their interest in serving on the IPAC. Any such supplemental materials may also be emailed to [IPAC@frb.gov](mailto:IPAC@frb.gov). The Privacy Act Statement for IPAC Member Selection, which describes the purposes, authority, effects of nondisclosure, and uses of this information, can be found at <https://www.federalreserve.gov/aboutthefed/ipac-privacy.htm>.

Submissions may also be mailed to the Board of Governors of the Federal Reserve System, Attn: Insurance Policy Advisory Committee, 20th Street and Constitution Ave. NW, Washington, DC 20551.

**FOR FURTHER INFORMATION CONTACT:** Thomas Sullivan, Associate Director, (202) 475-7656; Linda Duzick, Manager, (202) 728-5881; or Jan Bauer, Sr. Insurance Policy Analyst, (202) 475-7697, Division of Supervision and Regulation; or [IPAC@frb.gov](mailto:IPAC@frb.gov).

**SUPPLEMENTARY INFORMATION:** The Economic Growth, Regulatory Relief, and Consumer Protection Act established at the Board an Insurance Policy Advisory Committee (IPAC) to advise the Board on international capital standards and other insurance matters. This document advises individuals of the opportunity to be considered for appointment to the IPAC. To assist with the selection of IPAC members, the Board will consider the information submitted by the candidate along with other information that it independently obtains.

#### Council Size and Terms

The IPAC will have no more than 21 members. The initial IPAC members, selected in 2019, have staggered terms to provide the IPAC with continuity. Members chosen at subsequent times will be appointed to three-year terms unless the appointment is made to fill an unexpired term. Selected members will serve a three-year term on IPAC commencing on January 1, 2021, unless selected to fill an unexpired term. The Board will provide a nominal honorarium and will reimburse IPAC

members only for their actual travel expenses subject to Board policy.

#### Statement of Interest

The Statement of Interest for the IPAC collects the following contact information about the candidate:

- Full name;
- Address;
- Phone number; and
- Email address.

At their option, candidates may also provide additional information for consideration as part of their interest in serving on the IPAC.

#### Qualifications

IPAC candidates should be insurance experts. The Board seeks a diverse set of expert perspectives from the various sectors of the U.S. insurance industry including life insurance, property and casualty insurance and reinsurance, agents and brokers, academics, consumer advocates, and experts on issues facing underserved insurance communities and consumers. The Board also seeks relevant actuarial, legal, regulatory, and accounting expertise, as well as expertise on lines of business underwritten by its currently supervised population of insurance institutions.

IPAC members must be willing and able to participate in conference calls and prepare for and attend meetings in person. IPAC membership and attendance is not delegable.

By order of the Board of Governors of the Federal Reserve System, acting through the Director of the Division of Supervision & Regulation under delegated authority, June 29, 2020.

**Ann Misback,**  
*Secretary of the Board.*

[FR Doc. 2020-15102 Filed 7-13-20; 8:45 am]

**BILLING CODE P**

#### FEDERAL RESERVE SYSTEM

##### Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction

##### Correction

In the **Federal Register** of June 24, 2020, in FR Doc. 2020-13633, "Formations of, Acquisitions by, and Mergers of Bank Holding Companies" pursuant to the Bank Holding Company Act of 1956 and the Board's Regulation Y, under the heading, *Federal Reserve Bank of Chicago, Katz Acquisition Corporation, LLC, Tampa, Florida*; on page 37947, in the first column, at the end of the first full paragraph, the comment period end date is corrected to read July 24, 2020.

Interested persons may view the notice and submit comments as provided in 85 FR 37946 (June 24, 2020) no later than July 24, 2020.

Board of Governors of the Federal Reserve System, July 7, 2020.

**Yao-Chin Chao,**  
*Assistant Secretary of the Board.*

[FR Doc. 2020-14985 Filed 7-13-20; 8:45 am]

**BILLING CODE P**

#### FEDERAL RESERVE SYSTEM

##### Formations of, Acquisitions by, and Mergers of Savings and Loan Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Home Owners' Loan Act (12 U.S.C. 1461 *et seq.*) (HOLA), Regulation LL (12 CFR part 238), and Regulation MM (12 CFR part 239), and all other applicable statutes and regulations to become a savings and loan holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a savings association.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on whether the proposed transaction complies with the standards enumerated in the HOLA (12 U.S.C. 1467a(e)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington DC 20551-0001, not later than August 13, 2020.

*A. Federal Reserve Bank of Chicago* (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Forward Mutual Holding Company and Forward Financial, Inc., both of Marshfield, Wisconsin*; to convert from bank holding companies to a mutual holding company and a mid-tier stock savings and loan holding company, respectively, by retaining voting shares of Forward Bank, a state savings

association, also of Marshfield, Wisconsin, and indirectly engage in real estate development and management activities pursuant to section 238.53(b)(4)–(8) of Regulation LL.

Board of Governors of the Federal Reserve System, July 9, 2020.

**Yao-Chin Chao,**

*Assistant Secretary of the Board.*

[FR Doc. 2020–15182 Filed 7–13–20; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Supplemental Evidence and Data Request on Continuous Positive Airway Pressure Treatment for Obstructive Sleep Apnea in Medicare Eligible Patients

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), HHS.

**ACTION:** Request for supplemental evidence and data submissions.

**SUMMARY:** The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review on *Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea in Medicare Eligible Patients*, which is currently being conducted by the AHRQ's Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

**DATES:** *Submission Deadline* on or before 30 days after date of publication of this Notice.

**ADDRESSES:**

*Email submissions:* [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

*Print submissions:*

*Mailing Address:* Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.

*Shipping Address (FedEx, UPS, etc.):* Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:**

Jenae Benms, Telephone: 301–427–1496 or Email: [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea in Medicare Eligible Patients. AHRQ is conducting this systematic review pursuant to Section 902(a) of the Public Health Service Act, 42 U.S.C. 299a(a).

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on *Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea in Medicare Eligible Patients*, including those that describe adverse events. The entire research protocol is available online at: <https://www.ahrq.gov/research/findings/ta/index.html#supplemental>.

This is to notify the public that the EPC Program would find the following information on *Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea in Medicare Eligible Patients* helpful:

- A list of completed studies that your organization has sponsored for this indication. In the list, please *indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.*

- *For completed studies that do not have results on ClinicalTrials.gov*, a summary, including the following elements: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.

- *A list of ongoing studies that your organization has sponsored for this indication.* In the list, please provide the ClinicalTrials.gov trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.

- Description of whether the above studies constitute *ALL Phase II and above clinical trials* sponsored by your organization for this indication and an

index outlining the relevant information in each submitted file.

Your contribution is very beneficial to the Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program. This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ's EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: <https://www.effectivehealthcare.ahrq.gov/email-updates>.

*The systematic review will answer the following questions.* This information is provided as background. AHRQ is not requesting that the public provide answers to these questions.

### Contextual and Key Questions (KQ)

#### Contextual Questions

**CQ 1:** What measures related to apneas and hypopneas (e.g., apnea indices, hypopnea indices, and apnea-hypopnea indices with various measurements) or other measures (e.g., time spent with oxygen saturation below 90% or other cutoffs, electrophysiologic signal analysis metrics such as time and frequency domain analyses of heart beats) are used in contemporary research and clinical settings? How have standard definitions of these measures changed over time and what is the explanation for such changes?

**CQ 2:** What are commonly used sleep questionnaires and how have they been validated?

**CQ 3:** What treatment modalities for OSA are currently being marketed in the U.S.? What OSA treatments (experimental or approved) are currently being investigated in ongoing trials for patients as an alternative to CPAP?

**CQ 4:** What are the variable features of marketed CPAP devices?

**CQ 5:** What are the patient-centered health outcome goals and symptom relief goals of CPAP devices?

#### Key Questions

**KQ 1:** What is the efficacy, effectiveness, comparative effectiveness, and harms of CPAP devices to improve *clinically significant outcomes*?

**KQ 1a:** How are respiratory disturbance events (apnea, hypopnea,